Even if most patients in palliative care units presented with well-recognized risks factors
of venous thromboembolism (VTE) (eg: active cancer, bed rest, previous history of venous
thrombosis), the incidence of VTE in palliative setting is unknown. By consequence, the
efficacy and safety of antithrombotic prophylaxis in such a population is not established.
Indeed, patients admitted in palliative care units were not included in trials evaluating the
potential effect of antithrombotic drugs in regard to their poor prognosis at short term. In
addition, the main role of prophylaxis is to prevent sudden death from pulmonary emboli and
is thus a life prolonging therapy which is viewed as counterintuitive to palliative care
philosophy and inappropriate on grounds of futility. Nevertheless, the current use of Low
Molecular Weight Heparin in palliative care units seems to increase particularly in patients
with advanced malignancy. The identification of high hemorrhagic risks in palliative care
patients could help the decision of antithrombotic prophylaxis initiation. For this, the
investigators conducted a multicenter prospective longitudinal study.